Patient-reported outcomes in meta-analyses-part 2: methods for improving interpretability for decision-makers
- PMID: 24359184
- PMCID: PMC3984637
- DOI: 10.1186/1477-7525-11-211
Patient-reported outcomes in meta-analyses-part 2: methods for improving interpretability for decision-makers
Abstract
Systematic reviews and meta-analyses of randomized trials that include patient-reported outcomes (PROs) often provide crucial information for patients, clinicians and policy-makers facing challenging health care decisions. Based on emerging methods, guidance on improving the interpretability of meta-analysis of patient-reported outcomes, typically continuous in nature, is likely to enhance decision-making. The objective of this paper is to summarize approaches to enhancing the interpretability of pooled estimates of PROs in meta-analyses. When differences in PROs between groups are statistically significant, decision-makers must be able to interpret the magnitude of effect. This is challenging when, as is often the case, clinical trial investigators use different measurement instruments for the same construct within and between individual randomized trials. For such cases, in addition to pooling results as a standardized mean difference, we recommend that systematic review authors use other methods to present results such as relative (relative risk, odds ratio) or absolute (risk difference) dichotomized treatment effects, complimented by presentation in either: natural units (e.g. overall depression reduced by 2.4 points when measured on a 50-point Hamilton Rating Scale for Depression); minimal important difference units (e.g. where 1.0 unit represents the smallest difference in depression that patients, on average, perceive as important the depression score was 0.38 (95% CI 0.30 to 0.47) units less than the control group); or a ratio of means (e.g. where the mean in the treatment group is divided by the mean in the control group, the ratio of means is 1.27, representing a 27% relative reduction in the mean depression score).
References
-
- US Food and Drug Administration (FDA) Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville, MD: Department of Health and Human Services (US), Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati...] Accessed 5 Sept, 2013. - PubMed
-
- Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, Johnston BC, Karanikolas P, Vist G, Kunz R, Brozek J, Meerpohl J, Akl EA, Christensen R, Schünemann HJ. Preparing summary of findings tables: continuous outcomes. J Clin Epidemiol. 2013;11(2):173–183. doi: 10.1016/j.jclinepi.2012.08.001. - DOI - PubMed
-
- Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, Brozek J, Norris S, Meerpohl J, Djulbegovic B, Alonso-Coello P, Post PN, Busse JW, Glasziou P, Christensen R, Schünemann HJ. GRADE guidelines: 12: preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;11(2):158–172. doi: 10.1016/j.jclinepi.2012.01.012. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous